Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain.

This leads to relatively smooth (though not flawless) northbound trajectories and strong returns for most stocks over a ...

Vertex Pharmaceuticals' (NASDAQ: VRTX) remarkable momentum came to a screeching halt this week. The big biotech stock had been up well over 20% year to date. The main bad news with Vertex's Q1 results ...

With a market cap of $114.8 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a biotechnology company specializing in ...

Back in 2020, the company announced it would give up the development of VX-814, a potential treatment for alpha-1 antitrypsin ...

The stock's fall snapped a four-day winning streak.

This was the stock's fourth consecutive day of gains.